系统性硬化症胃肠道症状的自身抗体预测因素
该研究纳入526例系统性硬化症(SSc)患者,采用UCLA SCTC GIT 2.0问卷评估SSc相关胃肠道功能障碍(SSc-GI)的患病率与负担,并分析其与人口学、临床及血清学特征的关系。结果显示ACA、ARA及ENA阴性者SSc-GI疾病负担增加,PM-Scl相对保护,自身抗体与胃肠道负担的关联在高负担患者中尤为显著。
要点
- ACA、ARA及ENA阴性者SSc-GI疾病负担增加,PM-Scl相对保护。
- 自身抗体与胃肠道负担的关联在高负担患者中尤为显著。
- 反流和腹胀症状是SSc-GI中最突出的表现。
核心结论
- SSc患者中SSc-GI疾病负担显著,反流和腹胀症状最为突出。
- SSc标志性抗体可能预测SSc-GI风险增加,尤其是ACA和ARA,而PM-Scl可能具有保护作用。
研究设计与样本
- 队列纳入526例SSc患者,具有典型的疾病相关自身抗体分布(ACA、ARA、ATA、PM-Scl、U1RNP、U3RNP)。
- 患者完成UCLA SCTC GIT 2.0问卷以评估多领域功能与心理维度的GI疾病负担,问卷评分采用非参数和分位数回归分析。
主要发现
- ACA、ARA和ENA阴性者SSc-GI疾病负担增加,PM-Scl相对保护。
- 在分布分析中,自身抗体与GI疾病负担的关联在GI负担最高的患者中尤为显著。
临床怎么用
- 对SSc患者可依据ACA、ARA、ENA阴性及PM-Scl等标志性抗体识别SSc-GI高风险或相对保护人群。
- 关注反流和腹胀等突出症状,采用UCLA SCTC GIT 2.0问卷评估多维度GI负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the prevalence and burden of SSc-related gastrointestinal dysfunction (SSc-GI) and to evaluate associations with demographic, clinical and serological characteristics. METHODS: Patients completed the UCLA SCTC GIT 2.0 questionnaire for SSc-GI disease to assess the burden of GI disease across multiple functional and psychological domains. Questionnaire scores were assessed using non-parametric and quantile regression analyses. RESULTS: Our cohort included 526 patients with SSc, with a typical distribution of disease-associated autoantibodies (ACA, ARA, ATA, PM-Scl, U1RNP, U3RNP). We demonstrated associations between hallmark antibodies and the domain-specific burden of GI disease. In particular, ACA, ARA and ENA-negative demonstrated increased SSc-GI disease burden, while PM-Scl conferred relative protection. In a distributional analysis, associations with autoantibodies were particularly marked in those with the highest burden of GI disease. CONCLUSION: There is a significant burden of SSc-GI disease in patients with SSc; reflux and bloating symptoms are most prominent. SSc hallmark antibodies may predict increased risk of SSc-GI disease, in particular ACA and ARA, while PM-Scl may be protective.
引用
- Ahmed F, Maclean RH, Nihtyanova SI, et al. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 33909895. doi:10.1093/rheumatology/keab395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。